President and CEO of Targacept Inc. (TRGT, Financial) J Donald Debethizy sells 10,000 shares of TRGT on 08/31/2009 at an average price of $14.53 a share.
TARGACEPT INC is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease cognitive dysfunction in schizophrenia pain and depression as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept Inc. has a market cap of $370.5 million; its shares were traded at around $14.84 with and P/S ratio of 18.4.
TRGT is in the portfolios of Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC.
Recent Trades of Targacept Inc. by CEO:
Recent Trades of Targacept Inc. by CFO:
Recent Trades of Targacept Inc. by Directors and Officers:
TARGACEPT INC is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease cognitive dysfunction in schizophrenia pain and depression as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept Inc. has a market cap of $370.5 million; its shares were traded at around $14.84 with and P/S ratio of 18.4.
TRGT is in the portfolios of Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC.
Recent Trades of Targacept Inc. by CEO:
- Sell: President and CEO J Donald Debethizy sold 2,400 shares of TRGT stock on 08/24/2009 at the average price of $13.52; the price of the stock has increased by 9.76% since.
- Sell: President and CEO J Donald Debethizy sold 4,600 more shares of TRGT stock on 08/14/2009 at the average price of $13.51; the price of the stock has increased by 9.84% since.
- Sell: President and CEO J Donald Debethizy sold 5,700 more shares of TRGT stock on 08/07/2009 at the average price of $12.03; the price of the stock has increased by 23.36% since.
- Sell: President and CEO J Donald Debethizy sold 5,700 more shares of TRGT stock on 07/29/2009 at the average price of $11.27; the price of the stock has increased by 31.68% since.
- Sell: President and CEO J Donald Debethizy sold 2,600 more shares of TRGT stock on 07/28/2009 at the average price of $11.01; the price of the stock has increased by 34.79% since.
Recent Trades of Targacept Inc. by CFO:
- Sell: VP, CFO & Treasurer Alan A Musso sold 2,500 shares of TRGT stock on 08/24/2009 at the average price of $13.55; the price of the stock has increased by 9.52% since.
- Sell: VP, CFO & Treasurer Alan A Musso sold 4,500 more shares of TRGT stock on 08/14/2009 at the average price of $13.51; the price of the stock has increased by 9.84% since.
- Sell: VP, CFO & Treasurer Alan A Musso sold 5,700 more shares of TRGT stock on 08/07/2009 at the average price of $12.03; the price of the stock has increased by 23.36% since.
- Sell: VP, CFO & Treasurer Alan A Musso sold 5,263 more shares of TRGT stock on 07/29/2009 at the average price of $11.29; the price of the stock has increased by 31.44% since.
- Sell: VP, CFO & Treasurer Alan A Musso sold 3,037 more shares of TRGT stock on 07/28/2009 at the average price of $11.02; the price of the stock has increased by 34.66% since.
Recent Trades of Targacept Inc. by Directors and Officers:
- Buy: 10% Owner Partners L P/il Bvf bought 25,700 shares of TRGT stock on 07/13/2009 at the average price of $3.06; the price of the stock has increased by 384.97% since.
- Buy: Director Julia R Brown bought 7,500 shares of TRGT stock on 03/17/2009 at the average price of $3.03; the price of the stock has increased by 389.77% since.
- Sell: VP, Clin. Dev. & Reg. Affairs Geoffrey C Dunbar sold 10,000 shares of TRGT stock on 08/28/2009 at the average price of $14.03; the price of the stock has increased by 5.77% since.
- Sell: VP - Drug Discovery and Dev. William S Caldwell sold 7,000 shares of TRGT stock on 08/28/2009 at the average price of $14.36; the price of the stock has increased by 3.34% since.
- Sell: VP - Drug Discovery and Dev. William S Caldwell sold 6,780 more shares of TRGT stock on 08/11/2009 at the average price of $12.69; the price of the stock has increased by 16.94% since.
